NASDAQ: CRIS · Life Sciences · 4 alerts · CIK 1108205
Share price
$0.4358Close, Nov 16
Market cap
$4.15M
Shares outstanding
9.51MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Curis Inc filings on SEC EDGAR ↗
Curis, Inc. reported a total stockholders' equity of $2.55 million as of September 30, 2026, a decrease from $5.46 million at the end of 2025. The company continues to incur substantial losses, with an accumulated deficit reaching $1.29 billion, and management has identified conditions that raise substantial doubt about its ability to continue as a going concern.
Curis reported financial results for the third quarter of 2026 and provided an operational update on its TakeAim CLL and TakeAim Lymphoma clinical trials. The company highlighted progress in combining emavusertib with BTK inhibitors for the treatment of CLL and PCNSL, with initial data from the TakeAim CLL study expected in December 2026.
Term
Q3 2026
“The excitement among clinicians and patients reflects the clear unmet need in both CLL and PCNSL, where emavusertib has the potential to change the treatment landscape when combined with approved BTK inhibitors.”
Curis, Inc. received a delisting determination letter from Nasdaq on November 2, 2026, because its common stock closed below the $1.00 minimum bid price for 30 consecutive business days. Due to a previous 1-for-20 reverse stock split in July 2026 and an existing Panel Monitor, the company is not eligible for a standard compliance period and faces immediate delisting risk. The company intends to appeal the decision to a Nasdaq Hearings Panel to stay the delisting process.
Curis, Inc. entered into a securities purchase agreement to raise approximately $8.5 million through the sale of 16,666,680 shares of common stock (or pre-funded warrants) and accompanying common warrants at a combined price of $0.51 per share. The company intends to use the proceeds to fund research and development activities, specifically to support operations through its initial Chronic Lymphocytic Leukemia (CLL) data readout expected in December 2026.